Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

ASPR’s Portfolio of COVID-19 Medical Countermeasures under Investigation

There are no drugs or other therapeutics presently approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19. However, ASPR is sponsoring the development of a number of therapeutic products that are being made available under either FDA’s expanded access program and/or have been granted an Emergency Use Authorization by FDA.

Therapeutic Products

1. Remdesivir (Gilead Sciences, Inc.) Convalescent plasma (Multiple Contracts)Chloroquine or hydroxychloroquine (Multiple Contracts)

Diagnostic Tests 

Accula SARS-CoV-2 Test (Mesa Biotech)Xpert Xpress SARS-CoV-2 Test (Cepheid)Panther Fusion SARS-CoV-2  Assay (Hologic)NxTag CoV Extended Panel Assay (Luminex) Aries SARS-CoV-2 Test (Luminex)8.    LIASON SARS-CoV-2 S1/S2 IgG (DiaSorin Inc.)QIAstat-Dx RPS2  (Qiagen)

  • This page last reviewed: June 26, 2020